FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1
Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a selective targeting agent and drug carrier. Short peptid...
Main Authors: | Karolina Jendryczko, Julia Chudzian, Natalia Skinder, Łukasz Opaliński, Jakub Rzeszótko, Antoni Wiedlocha, Jacek Otlewski, Anna Szlachcic |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/10/2992 |
Similar Items
-
FGF1 protects FGFR1-overexpressing cancer cells against drugs targeting tubulin polymerization by activating AKT via two independent mechanisms
by: Jakub Szymczyk, et al.
Published: (2022-10-01) -
FGF/FGFR-Dependent Molecular Mechanisms Underlying Anti-Cancer Drug Resistance
by: Jakub Szymczyk, et al.
Published: (2021-11-01) -
Efficacy and Selectivity of FGF2-Saporin Cytosolically Delivered by PCI in Cells Overexpressing FGFR1
by: Aurora K. Vikan, et al.
Published: (2021-06-01) -
Identification of a peptide antagonist of the FGF1–FGFR1 signaling axis by phage display selection
by: Magdalena Lipok, et al.
Published: (2019-05-01) -
FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention
by: Yijun Wang, et al.
Published: (2021-03-01)